← Back
Data updated: Jun 28, 2026
NITROUS OXIDE OF CANADA
Pharma Pharmaceuticals
NITROUS OXIDE OF CANADA is a pharmaceutical company with 1 FDA-approved products.
2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
NITROUS OXIDE OF CANADA's Key Drugs
NITROUS OXIDE OF CANADA's core commercial portfolio centers on NITROUS OXIDE, USP — its most strategically important drugs approved in the last 15 years.
NITROUS OXIDE OF CANADA's Recent FDA Approvals
New NDA/BLA approvals for NITROUS OXIDE OF CANADA over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
NITROUS OXIDE OF CANADA's Therapeutic Areas
Disease areas where NITROUS OXIDE OF CANADA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
NITROUS OXIDE OF CANADA Pipeline Snapshot
Active clinical trials for NITROUS OXIDE OF CANADA across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NITROUS OXIDE, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-09-06
- Latest
- 2013-09-06
- Applications
- 1